{"entity":"gilead-sciences","id":"ent_gilead-sciences","name":"Gilead Sciences","wikidata":"Q663596","page":"https://asof.is/record/gilead-sciences","summary":"Gilead Sciences is an American biopharmaceutical company, headquartered in Foster City. It reported revenue of $29.44B for the period ended December 31, 2025.","title":"Gilead Sciences: revenue $29.44B","key_facts":[{"label":"Headquarters","value":"Foster City","claim":"clm_3AA77CFFBA18"},{"label":"Revenue","value":"$29.44B","recorded":"29,443,000,000 United States dollar","note":"to 2025-12-31","claim":"clm_5E2D1C5DC1DC"},{"label":"Ticker","value":"GILD · Nasdaq","claim":"clm_ACCCAF058EE1"}],"faq":[{"question":"Where is Gilead Sciences headquartered?","answer":"Foster City."},{"question":"What is Gilead Sciences's revenue?","answer":"$29.44B for the period ended December 31, 2025."}],"as_of":"2026-11-08","known_by":null,"since":null,"fact_pages":[{"predicate":"headquarters","page":"https://asof.is/record/gilead-sciences/headquarters","md":"https://asof.is/record/gilead-sciences/headquarters.md","json":"https://asof.is/v1/entities/gilead-sciences/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/gilead-sciences/revenue","md":"https://asof.is/record/gilead-sciences/revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/revenue"},{"predicate":"net_income","page":"https://asof.is/record/gilead-sciences/net_income","md":"https://asof.is/record/gilead-sciences/net_income.md","json":"https://asof.is/v1/entities/gilead-sciences/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/gilead-sciences/operating_income","md":"https://asof.is/record/gilead-sciences/operating_income.md","json":"https://asof.is/v1/entities/gilead-sciences/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/gilead-sciences/quarterly_revenue","md":"https://asof.is/record/gilead-sciences/quarterly_revenue.md","json":"https://asof.is/v1/entities/gilead-sciences/quarterly_revenue"}],"products":[],"coverage":{"entity":"gilead-sciences","name":"Gilead Sciences","kind":"organization","sources":[{"source":"wikidata","item":"Q663596","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":882095,"ticker":"GILD","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":533,"open":21,"retracted":0,"first":"1987-06-01","predicates":{"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"total_assets":{"claims":71,"open":1,"kind":"fact"},"operating_income":{"claims":19,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":56,"open":1,"kind":"fact"},"net_income":{"claims":19,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":51,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":56,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":25,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"website":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"research_and_development":{"claims":9,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":532,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":1,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_7B68B20F3E17","predicate":"cash_and_equivalents","value":"5,412,000,000 United States dollar","valid_from":"2022-12-31","valid_to":null,"published":"2023-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cash and equivalents: 5,412,000,000 United States dollar\", as of 2022-12-31. Claim clm_7B68B20F3E17, https://asof.is/claim/clm_7B68B20F3E17, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm.","url":"https://asof.is/claim/clm_7B68B20F3E17","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2022","published_at":"2023-02-22T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-22"}},{"id":"clm_3A93D2D56CBA","predicate":"cik","value":"0000882095","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences cik: 0000882095\", undated. Claim clm_3A93D2D56CBA, https://asof.is/claim/clm_3A93D2D56CBA, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_3A93D2D56CBA","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_58190642DD33","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences fiscal year end: 12-31\", undated. Claim clm_58190642DD33, https://asof.is/claim/clm_58190642DD33, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_58190642DD33","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_3AA77CFFBA18","predicate":"headquarters","value":"Foster City","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences headquarters: Foster City\", undated. Claim clm_3AA77CFFBA18, https://asof.is/claim/clm_3AA77CFFBA18, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_3AA77CFFBA18","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_79DB7756109C","predicate":"listed_on","value":"Nasdaq","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences listed on: Nasdaq\", undated. Claim clm_79DB7756109C, https://asof.is/claim/clm_79DB7756109C, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm.","url":"https://asof.is/claim/clm_79DB7756109C","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209518000008/a2017form10-k.htm","tier":"primary","publisher":null,"published_at":null},{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null},{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_075AC6F097D8","predicate":"net_income","value":"8,510,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences net income: 8,510,000,000 United States dollar\", as of 2025-12-31. Claim clm_075AC6F097D8, https://asof.is/claim/clm_075AC6F097D8, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_075AC6F097D8","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_44AE227A69DA","predicate":"operating_income","value":"10,022,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences operating income: 10,022,000,000 United States dollar\", as of 2025-12-31. Claim clm_44AE227A69DA, https://asof.is/claim/clm_44AE227A69DA, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_44AE227A69DA","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_4B6581046BE2","predicate":"quarterly_net_income","value":"2,429,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly net income: 2,429,000,000 United States dollar\", as of 2026-09-30. Claim clm_4B6581046BE2, https://asof.is/claim/clm_4B6581046BE2, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_4B6581046BE2","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_8490C244F9F5","predicate":"quarterly_operating_income","value":"3,462,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly operating income: 3,462,000,000 United States dollar\", as of 2026-09-30. Claim clm_8490C244F9F5, https://asof.is/claim/clm_8490C244F9F5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_8490C244F9F5","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_46B555B900FF","predicate":"quarterly_research_and_development","value":"1,101,000,000 United States dollar","valid_from":"2020-03-31","valid_to":null,"published":"2020-05-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly research and development: 1,101,000,000 United States dollar\", as of 2020-03-31. Claim clm_46B555B900FF, https://asof.is/claim/clm_46B555B900FF, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm.","url":"https://asof.is/claim/clm_46B555B900FF","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000013/0000882095-20-000013-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q1 FY2020","published_at":"2020-05-06T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q1 FY2020, filed 2020-05-06"}},{"id":"clm_64E20B8C7E0A","predicate":"quarterly_revenue","value":"8,300,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences quarterly revenue: 8,300,000,000 United States dollar\", as of 2026-09-30. Claim clm_64E20B8C7E0A, https://asof.is/claim/clm_64E20B8C7E0A, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_64E20B8C7E0A","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_B758636654A0","predicate":"registrant_name","value":"GILEAD SCIENCES, INC.","valid_from":"1994-02-14","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences registrant name: GILEAD SCIENCES, INC.\", as of 1994-02-14. Claim clm_B758636654A0, https://asof.is/claim/clm_B758636654A0, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_B758636654A0","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_EF2F795524C5","predicate":"research_and_development","value":"9,106,000,000 United States dollar","valid_from":"2019-12-31","valid_to":null,"published":"2020-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences research and development: 9,106,000,000 United States dollar\", as of 2019-12-31. Claim clm_EF2F795524C5, https://asof.is/claim/clm_EF2F795524C5, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm.","url":"https://asof.is/claim/clm_EF2F795524C5","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2019","published_at":"2020-02-25T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2019, filed 2020-02-25"}},{"id":"clm_5E2D1C5DC1DC","predicate":"revenue","value":"29,443,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences revenue: 29,443,000,000 United States dollar\", as of 2025-12-31. Claim clm_5E2D1C5DC1DC, https://asof.is/claim/clm_5E2D1C5DC1DC, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm.","url":"https://asof.is/claim/clm_5E2D1C5DC1DC","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-24T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-24"}},{"id":"clm_3ADDE79BC725","predicate":"shares_outstanding","value":"1,240,338,614 shares","valid_from":"2026-10-23","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences shares outstanding: 1,240,338,614 shares\", as of 2026-10-23. Claim clm_3ADDE79BC725, https://asof.is/claim/clm_3ADDE79BC725, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_3ADDE79BC725","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_44B0DF6C61E1","predicate":"sic_industry","value":"Biological Products, (No Diagnostic Substances) (2836)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences sic industry: Biological Products, (No Diagnostic Substances) (2836)\", undated. Claim clm_44B0DF6C61E1, https://asof.is/claim/clm_44B0DF6C61E1, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_44B0DF6C61E1","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_433BC2407C2F","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences state of incorporation: DE\", undated. Claim clm_433BC2407C2F, https://asof.is/claim/clm_433BC2407C2F, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_433BC2407C2F","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_ACCCAF058EE1","predicate":"ticker","value":"GILD","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences ticker: GILD\", undated. Claim clm_ACCCAF058EE1, https://asof.is/claim/clm_ACCCAF058EE1, accessed 2026-11-09. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095.","url":"https://asof.is/claim/clm_ACCCAF058EE1","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_53C30342724D","predicate":"total_assets","value":"51,408,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total assets: 51,408,000,000 United States dollar\", as of 2026-09-30. Claim clm_53C30342724D, https://asof.is/claim/clm_53C30342724D, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_53C30342724D","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_F5C77DE07AFE","predicate":"total_equity","value":"13,040,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-10-30","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences total equity: 13,040,000,000 United States dollar\", as of 2026-09-30. Claim clm_F5C77DE07AFE, https://asof.is/claim/clm_F5C77DE07AFE, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm.","url":"https://asof.is/claim/clm_F5C77DE07AFE","accessed":"2026-11-09"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-10-30T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-10-30"}},{"id":"clm_6FC170F46335","predicate":"website","value":"https://www.gilead.com/","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences website: https://www.gilead.com/\", undated. Claim clm_6FC170F46335, https://asof.is/claim/clm_6FC170F46335, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q663596.","url":"https://asof.is/claim/clm_6FC170F46335","accessed":"2026-11-09"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Gilead Sciences.","url":"https://www.gilead.com/"}},{"id":"clm_B694320241BE","predicate":"x_username","value":"GileadSciences","valid_from":"2011-06-02","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Gilead Sciences x username: GileadSciences\", as of 2011-06-02. Claim clm_B694320241BE, https://asof.is/claim/clm_B694320241BE, accessed 2026-11-09. Source: https://www.wikidata.org/wiki/Q663596.","url":"https://asof.is/claim/clm_B694320241BE","accessed":"2026-11-09"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q663596","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/GileadSciences","url":"https://www.gilead.com/"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}